Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

I use roflumilast for inverse psoriasis and tapinarof for thicker plaque psoriasis." Cheng said insurance considerations often come into play when deciding how to start psoriasis treatment.

Top-line results for the last cohort of patients in the Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) in 4Q 2025, where we have already demonstrated the ...

The researchers note that roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which targets inflammatory pathways central ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Psoriasis can occur near the eyes, causing redness, itching, dryness, and flaking skin. Once it’s correctly diagnosed, you can often manage it with topical treatments.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.